Institute for Sustainable Malaria Control, School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa.
Department of Biochemistry, Genetics and Microbiology, University of Pretoria, Pretoria, South Africa.
Front Cell Infect Microbiol. 2022 Jun 9;12:901971. doi: 10.3389/fcimb.2022.901971. eCollection 2022.
parasites have a complex life cycle that includes development in the human host as well as the vector. Successful transmission of the parasite between its host and vector therefore requires the parasite to balance its investments in asexual replication and sexual reproduction, varying the frequency of sexual commitment to persist within the human host and generate future opportunities for transmission. The transmission window is extended further by the ability of stage V gametocytes to circulate in peripheral blood for weeks, whereas immature stage I to IV gametocytes sequester in the bone marrow and spleen until final maturation. Due to the low gametocyte numbers in blood circulation and with the ease of targeting such life cycle bottlenecks, transmission represents an efficient target for therapeutic intervention. The biological process of transmission is a multistage, multifaceted process and the past decade has seen a much deeper understanding of the molecular mechanisms and regulators involved. Clearly, specific and divergent processes are used during transmission compared to asexual proliferation, which both poses challenges but also opportunities for discovery of transmission-blocking antimalarials. This review therefore presents an update of our molecular understanding of gametocyte and gamete biology as well as the status of transmission-blocking activities of current antimalarials and lead development compounds. By defining the biological components associated with transmission, considerations for the development of new transmission-blocking drugs to target such untapped but unique biology is suggested as an important, main driver for transmission-blocking drug discovery.
寄生虫具有复杂的生命周期,包括在人类宿主和媒介中发育。因此,寄生虫要在无性繁殖和有性生殖之间取得平衡,从而成功地在宿主和媒介之间传播寄生虫,就需要改变其有性生殖的频率,以在人类宿主中持续存在并产生未来的传播机会。V 期配子体能够在周围血液中循环数周,进一步延长了传播窗口期,而不成熟的 I 期至 IV 期配子体则在骨髓和脾脏中隔离,直到最终成熟。由于血液循环中的配子体数量较少,并且很容易针对这些生命周期瓶颈进行靶向治疗,因此传播成为治疗干预的有效靶点。传播的生物学过程是一个多阶段、多方面的过程,过去十年对涉及的分子机制和调节剂有了更深入的了解。显然,与无性繁殖相比,在传播过程中使用了特定且不同的过程,这既带来了挑战,也为发现阻断传播的抗疟药物提供了机会。因此,本文综述了我们对配子体和配子生物学的分子认识的最新进展,以及当前抗疟药物和先导化合物的阻断传播活性的现状。通过定义与传播相关的生物学成分,考虑开发针对这种未被开发但独特的生物学的新型阻断传播药物,作为阻断传播药物发现的一个重要的主要驱动力。